Game Day, Continued.
If you have certain types of metastatic non-small cell lung cancer (NSCLC), small moments mean so much. TECENTRIQ immunotherapy may be an option for you.
If you have certain types of metastatic non-small cell lung cancer (NSCLC), small moments mean so much. TECENTRIQ immunotherapy may be an option for you.
Our gratitude goes out to the individuals, families, and healthcare providers who participated in the clinical trials that led to the approval of TECENTRIQ in non-small cell lung cancer. Thank you for your courage in the fight against cancer.
TECENTRIQ® (atezolizumab) is an FDA-approved immunotherapy for certain adults with metastatic non-small cell lung cancer( mNSCLC). TECENTRIQ is thought to work by targeting the PD-L1 protein to help restore the body’s immune response to identify and attack cancer cells. TECENTRIQ may also affect normal cells.
TECENTRIQ is administered as infusions into a vein through an intravenous (IV) line.
TECENTRIQ can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. Serious side effects of TECENTRIQ may include lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications including graft-versus-host disease (GVHD) in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.